Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,375.90 | 19.70 | 0.21% |
CAC 40 | 8,139.20 | 62.20 | 0.77% |
DAX 40 | 24,152.14 | 29.23 | -0.12% |
Dow JONES (US) | 46,340.54 | 87.23 | 0.19% |
FTSE 100 | 9,396.86 | 27.89 | -0.30% |
HKSE | 25,888.51 | 22.09 | -0.09% |
NASDAQ | 22,789.64 | 119.56 | 0.53% |
Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
S&P 500 | 6,689.00 | 17.94 | 0.27% |
S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
SSE Composite Index | 3,916.23 | 4.02 | 0.10% |